A Multi-Center Study Subjects With Dry Eye Syndrome

* To investigate the safety and tolerability of EBI-005 ophthalmic solution compared to placebo in the treatment of patients with moderate to severe Dry Eye Syndrome (DES). * To evaluate pharmacokinetic (PK) parameters and immunogenicity of two different doses of EBI-005 ophthalmic solution. * To investigate the biological activity of multiple doses of EBI-005 ophthalmic solution compared to placebo as assessed by both objective and subjective assessments. * To investigate the comparative dose response of two different doses of EBI-005 ophthalmic solution. * To investigate the comparative tolerability of two different doses of EBI-005 ophthalmic solution. * To identify key biomarkers in the diagnosis and management of subjects with DES.